BioSpace News Archive

EOM Pharmaceutical Holdings, Inc. (“EOM”), a clinical-stage pharmaceutical company, today announced its name change from ImmunoCellular Therapeutics Ltd., to EOM Pharmaceutical Holdings, Inc.

Medikine, Inc. today announced preliminary safety, tolerability, and pharmacokinetic/pharmacodynamic data from its Phase 1 clinical trial in healthy subjects for its lead program, MDK-703, a peptide-based interleukin-7 (IL-7) mimetic with an extended half-life.

Presentations and demonstrations will highlight how modern clinical data infrastructure and analytics platforms and optimized processes accelerate increasingly complex trials.

According to Latest Report Study, the global precision oncology market size was estimated at around USD 59.4 billion in 2021 and it is projected to hit around USD 139.60 billion by 2030, growing at a CAGR of 9.96% from 2022 to 2030.

In 2021, the global retinal disorders treatment market value reached at US$ 9.99 billion and projected to hit US$ 19 billion by 2030, expanding growth at a CAGR of 7.1% from 2022 to 2030.

Allogene Therapeutics, Inc. today presented pre-clinical data on a novel approach to immune “cloaking” designed to protect AlloCAR T™ cells from rapid host rejection.

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the presentation of new data from five presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Myeloid Therapeutics, Inc. today presented multiple posters on its therapeutics platforms, ATAK™ CAR receptors and in vivo mRNA programming, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held in Boston, MA, November 8-12, 2022.

HotSpot Therapeutics, Inc. today announced the presentation of additional preclinical data on the Company’s Casitas B-lineage lymphoma proto-oncogene (CBL-B) program in two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology makes immune cells more effective in killing tumor cells, today announced the results of several studies of its INTASYL™ compounds.